We aimed to investigate the difference in efficacy of medical treatment of symptomatic benign prostatic hyperplasia (BPH) between normal and obese patients with BPH; obesity was determined by either body mass index (BMI) or waist circumference (WC). In this 12-week prospective observational study, a total of 175 patients aged o40 years with International Prostate Symptom Scores (IPSS) o12 points and prostate volume o20 ml were prospectively enrolled. The patients were divided into two groups according to BMI or WC. Patients received the doxazosin gastrointestinal therapeutic system (GITS) at a dose of 4 mg once per day for 12 weeks. The changes from baseline in the IPSS, maximal urinary flow rate (Q max ), post-void residual volume, quality of life (QoL) scores and adverse events (AEs) were analysed. Of the 175 enrolled patients, 132 completed the study. Sixty-seven patients had BMI .23 kg m 22 , and 43 had WC .90 cm. Obese patients represented by WC .90 cm or BMI o23 kg m 22 had a significantly greater prostate volume compared with non-obese patients at baseline. Total IPSS was significantly higher in the WC .90 cm group compared to the WC f90 cm group. Total IPSS was positively correlated with prostate volume (P50.031) and WC (P50.045). All groups showed significant improvements in total IPSS and QoL at 12 weeks. However, the improvement of total IPSS was greater in the high-BMI and high-WC groups. The most frequent AE was dizziness (n513), and it was significantly lower in the obese BPH patients. Obesity was associated with increased prostate volume and lower urinary tract symptoms. Alpha-blockers appear to be efficacious for controlling symptoms, especially in obese men.
INTRODUCTION
Lower urinary tract symptoms (LUTS) and obesity are common in older men and may greatly affect their quality of life. Furthermore, epidemiological data demonstrate increasing prevalence of not only LUTS secondary to benign prostatic hyperplasia (BPH) but also obesity as men age.
1, 2 The Korean National Health and Nutrition Surveys reported an increase in the prevalence of obesity in South Korea from 1995 to 2001 and an age-related increase in the prevalence of obesity in Korean adults in 2001. 3 The prevalence of clinical benign prostatic hyperplasia was reported to be 10.6%-31% in men over 50 years of age, with an age-related increase in South Korea. 4, 5 Positive associations between anthropometric measures of obesity and LUTS have been observed in several studies. [6] [7] [8] This association indicates that modifiable risk factors may play a role in the pathogenesis of BPH.
We previously reported that the number of patients treated for BPH is rapidly increasing in Korea, and, non-invasive medical therapy is increasingly being chosen as the primary treatment option. 9 Of the medications for BPH, the doxazosin gastrointestinal therapeutic system (GITS) has been effective and well tolerated as therapy for Korean BPH patients with or without concomitant hypertension. 10 Although there are many studies concerning the clinical efficacy of doxazosin GITS, there is a paucity of reports concerning the difference in efficacy between normal and obese patients. In the present study, we aimed to investigate the efficacy of doxazosin GITS in patients with BPH with respect to body mass index (BMI) and waist circumference (WC).
MATERIALS AND METHODS

Study design
This was a 12-week prospective observational study conducted in our institution, Yonsei University Health System from June 2009 to May 2010. Before initiating this study, approval was granted by the local institutional review board, and patients provided informed consent.
Eligible patients with BPH/LUTS attending a urology clinic for the first time were enrolled. At the initial visit, height, weight and WC were measured in all enrolled patients. The signs of BPH were assessed through the routine evaluation of BPH using transrectal ultrasound of the prostate, maximal urinary flow rate (Q max ) assessed by uroflowmetry, post-void residual volume (PVR) assessed by ultrasound, International Prostate Symptom Score (IPSS), urine analysis and serum prostate-specific antigen (PSA) determination. The BMI of each patient was calculated as the body weight in kilograms divided by the square of the height in meters. After the initial evaluation, patients were assigned to receive doxazosin GITS at a dose of 4 mg once per day for 12 weeks. During 4 and 12 weeks after medication start all patients were evaluated via IPSS, uroflowmetry (Q max ) and PVR. At each visit, adverse events (AEs) were recorded.
Patients
A total of 175 patients were prospectively enrolled in the study. All patients were divided into two groups, normal BMI (n589, 23 kg m 22 or less) and overweight or obese BMI (n586, 23 kg m -2 or above), according to the Asia-Pacific obesity criteria. 11 We also categorized patients into two groups based on WC: normal waist (f90 cm) and central obesity (.90 cm). The inclusion criteria were men 40 years of age and older with a total IPSS of 12 or higher and a prostate volume o20 ml as determined by transrectal ultrasound without any relevant medical history or underlying comorbidities. Patients were excluded if they had neurogenic bladder dysfunction, confirmed prostate cancer, acute or chronic urinary retention status, acute or chronic prostatitis within the previous 3 months, PSA levels .10 ng ml 21 , a history of recurrent urinary tract infection or bladder stones, and previous transurethral resection of the prostate or other surgical interventions related to BPH. Of the 175 enrolled patients, 132 completed the study. Forty-three discontinued the trial, of whom 17 were lost to follow-up, 6 discontinued because the drug was not effective and 17 experienced AEs (e.g., dizziness or hypotension) ( Figure 1 ).
Statistical analysis
The intent-to-treat population included all randomized patients who took one or more doses of the study drug.
All data are presented as mean6s.e.m. and we analysed the data using SPSS (version 12.0; Chicago, IL, USA). The changes from baseline in total IPSS, quality of life (QoL) scores, Q max and PVR were analysed using paired Student's t-tests. An independent t-test was used to compare data between the normal and high-BMI or -WC groups. After performing a covariate analysis of variance, adjusted for age and prostate volume, the significance of the differences in total IPSS, QoL scores, Q max and PVR among groups based on baseline BMI and WC was examined using ANCOVA with subsequent linear contrasts. Post hoc analysis compared the mean changes from baseline to week 12 in total IPSS, IPSS QoL scores, Q max and PVR using a two-sided P value of ,0.05 to determine significance. The chi-square test was used to determine the statistical significance of differences in AEs between the normal BMI (n589, 23 kg m 22 or less) and obese BMI (n586, 23 kg m 22 or above) groups or normal waist and central obesity groups. We used linear regression to examine the prognostic factors for the improvement of total IPSS. A P value of ,0.05 was considered significant. Figure 1 , and the baseline clinical characteristics according to BMI or WC are summarized in Table 2) . Figure 2 shows the changes in the total IPSS and QoL scores for normal and obese patients after alpha-blocker medication (4 and 12
RESULTS
Details about the patients enrolled are shown in
Figure 1 Details of subjects assigned to the study treatment. BMI, body mass index.
Comparison of clinical efficacy of medical treatment
. All groups showed significant improvements in total IPSS and QoL scores at 12 weeks. The mean changes in total IPSS from baseline to 12 weeks were 29.3 (44.5%) and 28.1 (39.5%) points for the high-BMI (P50.022) and low-BMI groups (P50.039), respectively, and 29.8 (43.8%) and 27.4 (38.7%) points for the high-WC (P50.027) and low-WC groups (P50.031), respectively. Compared with the non-obese men, the high-BMI and high-WC groups showed greater reductions in total IPSS at week 12 (P50.034 and P50.021, respectively). Improvement of the QoL score was not different among groups; all groups showed improvements in QoL at 12 weeks. In the linear regression analysis, the change in the total IPSS between baseline and week 12 following alpha-blocker medication was positively correlated with baseline WC (P50.028). Q max significantly improved at week 12 (12.3 ml s 21 ) only in the high-WC group. The high-BMI group had a greater reduction in PVR (223.1 ml) from baseline compared to the other groups at week 12. In all, 17 treatment-related AEs were reported (12.9%). The most frequent AE was dizziness, reported by 13 patients (9.8%). Other AEs were postural hypotension (two, 1.5%), gastrointestinal disorder (one patient with gastritis, 0.7%) and prostatic disorder (one patient with aggravation of chronic perineal discomfort, 0.7%). Dizziness was significantly higher in the low-BMI group (n59, 10.1%) compared with the high-BMI group (n54, 4.7%, P50.042).
DISCUSSION
Our data demonstrate that the total IPSS was positively correlated with central obesity, as represented by waist circumference and prostate volume. Lee et al. 12 found that centrally obese men had lower testosterone concentrations and greater prostate volumes. Obesity raises oestrogen levels and free and total estradiol concentrations, while lowering free and total testosterone and serum globulin-binding protein levels. 13 Greater oestrogen levels in the environment of age-and obesity-induced lower testosterone levels may affect prostate cell growth. However, the extent to which obesity may influence BPH according to sex steroid hormones should be further investigated.
McVary et al. 14 demonstrated that increased sympathetic tone (autonomic hyperactivity) can result in LUTS and subjective voiding complaints. In particular, abdominal obesity increases the oestrogento-androgen ratio and may increase sympathetic nervous activity, both of which are known to influence the development of BPH and the severity of LUTS. 15 Among the indices of overweight and body adipose tissue distribution, it is visceral adiposity that is most closely related with The baseline data of the initially enrolled 175 patients are balanced with that of the 132 patients who finished the study. Comparison of clinical efficacy of medical treatment SH Lee et al 730 sympathetic overactivity. Among the obese patients, the whole body norepinephrine spillover rate is quantitatively linked to waist circumference. 16 Sympathetic nerve firing rates measured by microneurography have been reported to be 55% higher in men with elevated abdominal visceral fat levels than in men with only subcutaneous obesity. This increased sympathetic activity in centrally obese men is involved in LUTS/BPH, with norepinephrine and alpha1-adrenoceptors representing a common link. 17, 18 Interestingly, we observed significantly greater improvement in the mean change in total IPSS from baseline to week 12 in the high-BMI and -WC groups, even though the low BMI or low WC groups also showed significant improvements at week 12. Furthermore, the centrally obese BPH/LUTS patients showed significant improvement in Q max following alpha-blocker medication at week 12. Obesity is characterized by enlarged depots of adipose tissue, which are metabolically active and secrete numerous hormones and proteins that influence local adipocyte biology as well as distant organ systems. 19, 20 Leptin and tumor-necrosis factor-alpha are hormones secreted from adipose tissue that affect the ingestion of food and body weight. 21 It is also known that leptin stimulates the cellular proliferation of BPH. 22 Ueshiba and Miyachi 23 reported that treatment with the doxazosin improved dyslipidemia in obesity patients. Furthermore, circulating tumor-necrosis factor-alpha and leptin levels decreased significantly within 3 months of doxazosin treatment. 23 Therefore, doxazosin GITS might have a beneficial effect on adipose endocrine activity in obese patients with BPH.
We previously reported that individuals with more severe IPSS and larger prostate volumes have a higher risk of medical treatment failure, a result that is partially in conflict with the current results. 24 However, in that report we did not include the anthropometric parameters of BPH patients, and we included BPH patients taking 5-alpha-reductase inhibitors. Our results suggest that the effectiveness of alpha-blocker therapy is more complicated and that other factors should be further evaluated in addition to the parameters related to BPH or the clinical pharmacokinetics of doxazosin GITS. In addition, in our study we could not identify significant prognostic factors of non-response to doxazosin GITS due to the limited number of medical treatment failures. Therefore, further study based on a large sample size is needed to elucidate these factors.
This trial should be interpreted within the context of its limitations. It has a relatively short follow-up period and a small sample size despite being a prospective study. However, considering the increasing prevalence of concomitant comorbidities (e.g., hypertension and diabetes mellitus), the size of our sample of patients without any relevant medical history or underlying comorbidities might be adequate to determine statistical significance.
In our study, obesity was associated with increased prostate volume and lower urinary tract symptoms in BPH patients. Doxazosin GITS appears to be safe and efficacious for controlling symptoms, especially in obese men with BPH.
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